PharmiWeb
Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pru
BRIDGEWATER, NJ / ACCESSWIRE / October 30, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic ...
5 days ago